Floatz logo

ct-0508

HER2-positive Gastric Cancer

Carisma Therapeutics IncCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

283 Active assets in the HER2-positive Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

ct-0508 is also rated in:

adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
bile duct cancerDormant
CC
Indicative ·
43 / 100
View asset →
HER2 positive breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →